HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis

June 21st 2024

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

Dr Forsyth on Leptomeningeal Disease in HER2+ Breast Cancer and TNBC

June 18th 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

Dr Forsyth on the Investigation of Intrathecal Dendritic Cells for HER2+/TNBC Leptomeningeal Disease

June 11th 2024

Peter Forsyth, MD, discusses a study of intrathecal dendritic cells in patients with leptomeningeal disease from TNBC or HER2-positive breast cancer.

Subcutaneous Pertuzumab/Trastuzumab Maintains Comparable Efficacy/Safety vs IV Formulations in HER2+ Breast Cancer

June 7th 2024

Long-term outcomes with subcutaneous pertuzumab/trastuzumab plus chemo were comparable to the IV combo in HER2+ early breast cancer.

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

June 5th 2024

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Dr Foldi on the Evolving Treatment Landscape of ADCs in HER2+ Breast Cancer

June 4th 2024

Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.

Atezolizumab Elicits Numerical Improvement in 3-Year EFS, DFS in HER2+ Early Breast Cancer

May 30th 2024

Adding atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy produced improved EFS and DFS rates in HER2-positive early breast cancer.

Dr Foldi on the Impact of ILD in HER2+ Breast Cancer Treatment

May 29th 2024

Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.

Dr Tiwari on the Current Treatment Paradigms for HER2-Positive and HER2-Low Breast Cancers

May 22nd 2024

Shruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.

Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

May 19th 2024

A real-world study dives into treatment sequencing data and indicates most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in the US.

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Dr Nye on Paradigm Shifts in the Management of HR+ Breast Cancer

May 16th 2024

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Dr Tripathy on the Treatment of HER2+ Breast Cancer

May 15th 2024

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Dr Tripathy on Real-World HER2 Testing and CDK4/6 Inhibitor Use in HER2+ Breast Cancer

May 13th 2024

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

Dr Tripathy on the HER2+ Breast Cancer Treatment Paradigm

May 1st 2024

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Tumor Intrinsic Subtype Affects Relationship Between pCR and EFS in ERBB2+/HER2+ Early Breast Cancer

April 30th 2024

Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.